AKT1 and breast carcinoma: Combination treatment targeting BAG-1 with small molecule protein-protein interaction inhibitors and HER2 with trastuzumab synergistically reduces breast cancer cell growth, which is accompanied by attenuation of protein synthesis and induction of G1/S cell cycle arrest through the ERK and AKT pathways.